Phase III Study of PI-88 in Post-resection Hepatocellular Carcinoma
Trial ID or NCT#
Status
Purpose
The purpose of this study is to determine if PI-88 is effective and safe in patients who have had surgery to remove primary liver cancer.
Official Title
A Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-group, International, Multicentre Phase III Trial of PI-88 in the Adjuvant Treatment of Post-resection Hepatocellular Carcinoma
Eligibility Criteria
- * Histologically-proven primary hepatocellular carcinoma with curative resection performed in the 4 - 6 weeks prior to randomisation.* ECOG performance status 0 to 2* Child Pugh classification A or B
- Key
- * Any evidence of tumour metastasis or co-existing malignant disease* Any prior recurrence of HCC or any liver resection prior to the most recent procedure* History of prior HCC therapy
Investigator(s)
Contact us to find out if this trial is right for you.
Contact
Kerry Hsieh
6507247245
View on ClinicalTrials.gov